Nanoparticle-based oral drug delivery system for an injectable antibiotic - Streptomycin: Evaluation in a murine tuberculosis model

Chemotherapy

Volumn 53, Issue 6, 2007, Pages 437-441

  Pandey, Rajesh ^a   Khuller, Gopal K ^a  

^a POSTGRADUATE INSTITUTE OF MEDICAL EDUCATION AND RESEARCH   (India)

Author keywords

Bioavailability; Chemotherapy; Drug delivery; Poly lactide co glycolide

Indexed keywords

ISONIAZID; NANOPARTICLE; POLYGLACTIN; PYRAZINAMIDE; STREPTOMYCIN SULFATE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIMICROBIAL ACTIVITY; ARTICLE; CONTROLLED STUDY; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DELIVERY SYSTEM; DRUG DISPOSITION; DRUG DISTRIBUTION; DRUG FORMULATION; DRUG SYNTHESIS; DRUG TISSUE LEVEL; EMULSION; FEMALE; MALE; MOUSE; MYCOBACTERIUM TUBERCULOSIS; NANOENCAPSULATION; NONHUMAN; PARTICLE SIZE; PRIORITY JOURNAL; SINGLE DRUG DOSE; TUBERCULOSIS;

ADMINISTRATION, ORAL; ANIMALS; ANTI-BACTERIAL AGENTS; DISEASE MODELS, ANIMAL; DRUG DELIVERY SYSTEMS; FEMALE; LACTIC ACID; MALE; MICE; MICE, INBRED STRAINS; MICROBIAL SENSITIVITY TESTS; MYCOBACTERIUM TUBERCULOSIS; NANOSTRUCTURES; PLASMA; POLYGLYCOLIC ACID; POLYMERS; STREPTOMYCIN; TUBERCULOSIS;

EID: 36049001769     PISSN: 00093157     EISSN: None     Source Type: Journal    
DOI: 10.1159/000110009     Document Type: Article

References (22)

1. Nuermberger E, Grosset J: Pharmacokinetic and pharmacodynamic issues in the treatment of mycobacterial infections. Eur J Clin Microbiol Infect Dis 2004;23:243-255.
2. Peloquin CA, Berning SE, Nitta AT, Simone PM, Goble M, Huitt GA, Iseman MD, Cook JL, Curran-Everett D: Aminoglycoside toxicity: daily versus thrice-weekly dosing for treatment of mycobacterial diseases. Clin Infect Dis 2004;38:1538-1544.
3. Turnidge J: Pharmacodynamics and dosing of aminoglycosides. Infect Dis Clin N Am 2003;17:503-528.
4. World Health Organization, 2003: Treatment of tuberculosis: guidelines for national programmes, ed 3. Geneva, WHO, WHO/CDS/TB/2003.313.
5. Sánchez-Silos RM, Pérez-Giraldo C, Blanco MT, Morán FJ, Hurtado C, Gómez-García AC: Resistance to vancomycin, LY333328, ciprofloxacin and trovafloxacin of community-acquired and nosocomial strains of Enterococcus faecalis isolated in Badajoz (Spain) with and without high-level resistance to streptomycin and gentamicin. Chemotherapy 2001;47:415-420.
6. Florence AT, Hussain N: Transcytosis of nanoparticle and dendrimer delivery systems: evolving vistas. Adv Drug Deliv Rev 2001;50(suppl 1):S69-S89.
7. Pandey R, Zahoor A, Sharma S, Khuller GK: Nano-encapsulation of azole antifungals: potential applications to improve oral drug delivery. Int J Pharm 2005;301:268-276.
8. Pandey R, Zahoor A, Sharma S, Khuller GK: Nanoparticle encapsulated antitubercular drugs as a potential oral drug delivery system against murine tuberculosis. Tuberculosis (Edinb) 2003;83:373-378.
9. Sharma A, Pandey R, Sharma S, Khuller GK: Chemotherapeutic efficacy of poly(DL-lactide-co-glycolide) nanoparticle encapsulated antitubercular drugs at sub-therapeutic dose against experimental tuberculosis. Int J Antimicrob Agents 2004;24:599-604.
10. Pandey R, Sharma S, Khuller GK: Chemotherapeutic efficacy of nanoparticle encapsulated antitubercular drugs. Drug Deliv 2006;13:287-294.
11. USP 24/NF 18, 2000, US Pharmacopeial Convention, Rockville, pp 1645-1646.
12. Adams E, Rafiee M, Roets E, Hoogmartens J: Liquid chromatographic analysis of streptomycin sulfate. J Pharm Biomed Anal 2000;24:219-226.
13. Lalande V, Truffot-Pernot C, Paccaly-Moulin A, Grosset J, Ji B: Powerful bactericidal activity of sparfloxacin (AT-4140) against Mycobacterium tuberculosis in mice. Antimicrob Agents Chemother 1993;37:407-413.
14. Pandey R, Khuller GK: Chemotherapeutic potential of alginate-chitosan microspheres as antitubercular drug carriers. J Antimicrob Chemother 2004;53:635-640.
15. Lounis N, Maslo C, Truffot-Pernot C, Grosset J, Boelaert RJ: Impact of iron loading on the activity of isoniazid or ethambutol in the treatment of murine tuberculosis. Int J Tuberc Lung Dis 2003;7:575-579.
16. Kayser O, Lemke A, Hernandez-Trejo N: The impact of nanobiotechnology on the development of new drug delivery systems. Curr Pharm Biotechnol 2005;6:3-5.
17. Jiao Y, Ubrich N, Marchand-Arvier M, Vigneron C, Hoffman M, Lecompte T, Maincent P: In vitro and in vivo evaluation of oral heparin-loaded polymeric nanoparticles in rabbits. Circulation 2002;105:230-235.
18. Ubrich N, Schmidt C, Bodmeier R, Hoffman M, Maincent P: Oral evaluation in rabbits of cyclosporin-loaded Eudragit RS or RL na noparticles. Int J Pharm 2005;288:169-175.
19. Firsov AA, Zinner SH, Lubenko IY, Portnoy YA, Vostrov SN: Simulated in vitro quinolone pharmacodynamics at clinically achievable AUC/MIC ratios: advantage of I E over other integral parameters. Chemotherapy 2002;48:275-279.
20. Gangadharam PR, Ashtekar DR, Flasher DL, Duzgunes N: Therapy of Mycobacterium avium complex infections in beige mice with streptomycin encapsulated in sterically stabilized liposomes. Antimicrob Agents Chemother 1995;39:725-730.
21. Gurkan H, Yalabik-Kas HS, Hincal AA, Ercan MT: Streptomycin sulphate microspheres: formulation and in vivo distribution. J Microencapsul 1986;3:101-108.
22. Zhang Z, Lu B, Shu G, Xie H, Yi Q, He Y, Wang J: Study on the lung targeting gelatin microspheres of streptomycin sulphate (in Chinese). Hua Xi Yi Ke Da Xue Xue Bao 1995;26:167-171.